

What is claimed is:

1. An antibody that binds to HER2, comprising heavy chain and light chain, wherein: (1) the heavy chain comprises a heavy chain constant region and a heavy chain variable region; and (2) the light chain comprises a light constant region and light chain variable region, and wherein:
 - (a) the heavy chain variable region comprises CDRs of SEQ ID NOs: 2, 3, and 4;
 - (b) the heavy chain constant region comprises SEQ ID NO: 17;
 - (c) the light chain variable region comprises CDRs of SEQ ID NO:8, 9, and 10; and
 - (d) the light chain constant region comprises SEQ ID NO:41.
2. The antibody of claim 1, wherein the light chain comprises SEQ ID NO:42.
3. The antibody of claim 1 or claim 2, wherein the heavy chain comprises SEQ ID NO:18.
4. An antibody-drug conjugate (ADC), comprising the antibody of any one of claims 1-3, wherein the antibody is conjugated to a therapeutic agent via (1) the cysteine residue in the heavy chain constant region at position 173 of SEQ ID NO:17 and (2) the cysteine residue in the light chain constant region at position 76 of SEQ ID NO:41.
5. The ADC of claim 4, wherein the therapeutic agent is selected from the group consisting of: a cytotoxic agent, a cytostatic agent, a chemotherapeutic agent, a toxin, a radionuclide, a DNA, an RNA, an siRNA, a microRNA, a peptide nucleic acid, a non-natural amino acid, a peptide, an enzyme, a fluorescent tag, biotin, and any combination thereof.
6. The ADC of claim 4 or 5, wherein the therapeutic agent is conjugated to the antibody via a linker.
7. The ADC of claim 6, wherein the linker is cleavable.
8. The ADC of claim 6 or 7, where the linker comprises vc, mc, MalPeg6, m(H2O)c, m(H2O)cvc, or a combination thereof.
9. The ADC of any one of claims 6-8, wherein the linker is vc.
10. The ADC of any one of claims 4-9, wherein the therapeutic agent is an auristatin or tubulysin.
11. The ADC of any one of claims 4-10, wherein the therapeutic agent is an auristatin.
12. The ADC of claim 11, wherein the auristatin is selected from the group consisting of 0101, 8261, 6121, 8254, 6780, 0131, MMAD, MMAE, and MMAF.
13. A pharmaceutical composition comprising the ADC of any one of claims 4-12 and a pharmaceutically acceptable carrier.
14. The ADC of any one of claims 4-12, or the composition of claim 13, for use as a medicament.
15. The ADC of any one of claims 4-12, or the composition of claim 13, for use for the treatment of cancer.